Biolase (BIOL) Misses Q1 EPS by 4c

Biolase (NASDAQ: BIOL) reported Q1 EPS of ($0.07), $0.04 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $11 million versus the consensus estimate of $11.9 million.

For earnings history and earnings-related data on Biolase (BIOL) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Benchmark Reiterates Buy Rating on Odysight.AI Inc. (ODYS)
• BWS Financial Downgrades Inter Parfums (IPAR) to Sell